Early Australian research on a new BTK inhibitor is showing promise in patients with relapsed/refractory B-cell malignancies both as a single agent and in a novel triple combination with two other new drugs. Speaking to the limbic at ASH 2019, lead investigator Associate Professor Chan Cheah said the oral BTK inhibitor TG-1701 had previously been ...
Novel BTK inhibitor therapy trialled in Australia for lymphoma
By Mardi Chapman
17 Dec 2019